Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis

Clinical Therapeutics

Volumn 22, Issue 1, 2000, Pages 40-52

  Krug, Hollis ^a   Broadwell, Larry K ^c   Berry, Martin ^c   Delapp, Ralph ^b   Palmer, Robert H ^b   Mahowald, Maren ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SmithKline Beecham Pharmaceuticals ^*

Author keywords

Gastrointestinal tolerability; Nabumetone; Naproxen; Rheumatoid arthritis

Indexed keywords

NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 0033962407     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87976-X     Document Type: Article

References (26)

1. 1. Cush JJ, Jasin HE, Johnson R, Lipsky PE. Relationship between clinical efficacy and laboratory correlates of inflammatory and immunologic activity in rheumatoid arthritis patients treated with nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1990; 33:623-633.
2. 2. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1983;74:820-828.
3. 3. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(Suppl 26):18-24.
4. 4. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med. 1991;115:787-796.
5. 5. Simon LS, Hatoum HT, Bittman RM, et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial. Fam Med. 1996;28:204-210.
6. 6. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998;104(Suppl 3A):23S-29S.
7. 7. Scheiman JM. NSAIDs: Gastrointestinal injury and cytoprotection. Gastroenterol Clin North Am. 1996;25:279-298.
8. 8. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
9. 9. Singh G, Terry R, Ramey DR, et al. Comparative GI toxicity of NSAIDs. Arthritis Rheum. 1997;40(Suppl 9):S115. Abstract.
10. 10. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br Med J. 1996; 312:1563-1566.
11. 11. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. Br Med J. 1997;315:1333-1337.
12. 12. Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology. 1995;3:351-361.
13. 13. Porro GB, Montrone F, Petrillo M, et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol. 1995;90:1485-1488.
14. 14. Roth SH, Bennett R, Caldron P, et al. A long-term endoscopic evaluation of patients with arthritis treated with nabumetone vs. naproxen. J Rheumatol. 1994;21: 1118-1123.
15. 15. Lister BJ, Poland M, DeLapp R. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med. 1993;95(Suppl 2A):2S-9S.
16. 16. Eversmeyer W, Poland M, DeLapp RE, Jensen CP. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med. 1993; 95(Suppl 2A):10S-18S.
17. 17. Arnett FC, Edworthy SM, Block DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
18. 18. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140:659-662.
19. 19. Hochberg MC, Chkang W, Dwash I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in RA. Arthritis Rheum. 1992;35:498-502.
20. 20. Meenan RF, Mason JH, Anderson JJ, et al. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status questionnaire. Arthritis Rheum. 1992;35:1-10.
21. 21. Mason JH, Anderson JJ, Meenan RF, et al. The Rapid Assessment of Disease Activity in Rheumatology (RADAR) questionnaire. Validity and sensitivity to change of a patient self-report measure of joint count and clinical status. Arthritis Rheum. 1992;35:156-162.
22. 22. Pincus T, Griffin M. Gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs: New insights from observational studies and functional status questionnaires. Am J Med. 1991;90: 209-212.
23. 23. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
24. 24. Fleischmann RM. A controlled study comparing the effects of nabumetone, ibuprofen and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
25. 25. Bernhard GC, Appelrouth DJ, Bankhurst AD, et al. Long-term treatment of rheumatoid arthritis comparing nabumetone with aspirin. Am J Med. 1987;83(Suppl 4B): 44-49.
26. 26. Emery P, Clarke A, Williams P, et al. Nabumetone compared with naproxen in the treatment of rheumatoid arthritis: A multicenter, double-blind, randomized, parallel group trial in hospital outpatients. J Rheumatol. 1992;19(Suppl 36):41-47.